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ABSTRACT 
 
Glucose-regulated protein 78 (GRP78) is a stress sensor which interacts with unfolded 
protein response (UPR) activators in the endoplasmic reticulum (ER). The aim of this study 
was to test the hypothesis that GRP78 has distinct functional roles in mediating the effects of 
ER stress in neuroblastoma compared to other neuroectodermal cancer types. GRP78 was 
knocked down or overexpressed in neuroectodermal tumour cell lines. Protein and transcript 
expression were measured using Western blotting, confocal microscopy and real-time 
polymerase chain reaction; cell stress was assessed by measurement of oxidative stress and 
accumulation of ubiquitinated proteins and cell response by measurement of apoptosis and 
cell viability. Neuroblastoma cells were more sensitive to ER stress than melanoma and 
glioblastoma cells. GRP78 knockdown increased stress sensitivity of melanoma and 
glioblastoma cells, but not neuroblastoma cells. Over-expression of GRP78 decreased the 
stress sensitivity of melanoma and glioblastoma cells but, in contrast, increased the stress 
sensitivity of neuroblastoma cells by activation of caspase-3-independent cell death and 
substantially increased the expression of UPR activators, particularly inositol-requiring 
element 1 (IRE1). The results from this study suggest that cell-type specific differences in the 
relationships between GRP78 and the UPR activators, particularly IRE1, may determine 
differential sensitivity to ER stress.   
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Survival in heterogeneous microenvironments is a defining characteristic of metastatic 
tumour cells, and relies on an ability to adapt to varying degrees and types of stress [Kenific 
et al., 2010]. Understanding how to abrogate selectively the homeostatic mechanisms 
allowing cancer cells to survive outside their normal tissue environment is important for 
developing strategies to limit metastasis. The endoplasmic reticulum (ER) has a key role in 
sensing stress and in providing the scaffold, quality control and redox environment for 
correctly assembling newly-synthesised proteins. Disrupting ER function leads to the 
accumulation of unfolded or mis-folded proteins and activation of the Unfolded Protein 
Response (UPR), a homeostatic mechanism which may represent a target for controlling 
tumour metastasis. In this context, the protein-folding chaperone glucose-regulated protein 78 
(GRP78) has a key role in sensing ER stress and facilitating adaptive responses.  
GRP78 has high affinity for unfolded or mis-folded proteins and interactions with 
such substrates result in its dissociation from the UPR activators Protein kinase-like ER 
kinase (PERK), Inositol-Requiring Element 1 (IRE1) and Activating Transcription Factor 6 
(ATF6) [Schroder, 2006]. PERK release facilitates kinase activation by autophosphorylation-
induced homodimerisation, leading to attenuation of general protein synthesis [Bertolotti et 
al., 2000; Harding et al., 1999], while allowing translation of mRNA for pro-survival and 
pro-death stress-response proteins [Harding et al., 2000]; these proteins include Activating 
Transcription Factor 4 (ATF4), which in turn stimulates synthesis of chaperones, including 
GRP78, other proteins involved in homeostasis [Fels, 2006] and, under prolonged or severe 
stress, the pro-apoptotic transcription factor growth arrest and DNA damage induced gene 
153 (GADD153) [Wing et al., 1996]. Negative feedback inhibition of PERK, and eIF2α de-
phosphorylation [Kebache et al., 2004; Van Huizen et al., 2003] as stress is resolved, restores 
normal translation capacity.  
Once released from GRP78, oligomerization and autophosphorylation of IRE1, a 
trans-membrane protein kinase endoribonuclease, results in RNase-domain activation and 
splicing of mRNA for X-box binding protein 1 (XBP-1). Downstream events of IRE1 
activation include regulation of ER-resident chaperones and promotion of death via activation 
of GADD153and c-Jun N-terminal kinase (JNK) [Urano et al., 2000]. IRE1 also 
phosphorylates tumour necrosis factor receptor 2 (TRAF2) leading to activation of JNK and 
caspase-independent apoptosis via Bax and pro-apoptotic factors [Kroemer et al., 2007]. 
ATF6 released from GRP78 is cleaved in the Golgi to an active transcription factor which 
binds to promoters containing ER-stress response elements and regulates expression of ER-
stress-related proteins such as GRP78, XBP-1 and GADD153 [Yoshida et al., 2000]. 
Although PERK, IRE1 and ATF6 appear to have separate roles in stress signalling, ATF6 has 
functional overlap with PERK and IRE1 signalling pathways. 
Recent studies to understand the cellular role of GRP78 in tumour cells have 
suggested that increased GRP78 expression in melanoma and glioblastoma promotes cell 
survival and correlates with poor prognosis [Hersey and Zhang, 2008; Lee et al., 2008; 
Liquing et al., 2009]; conversely, increased GRP78 expression in neuroblastoma may 
correlate with greater stress sensitivity and better prognosis [Hsu et al., 2005]. These 
conflicting reports imply that GRP78 has different roles as a sensor of ER stress in different 
types of neuroectodermal tumours. The aim of this study was to test the hypothesis that 
GRP78 has functionally- or mechanistically-distinct roles in mediating the effects of ER 
stress in neuroblastoma compared to other neuroectodermal cell types.  
 
MATERIALS AND METHODS 
GROWTH AND MAINTENANCE OF CELL LINES  
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SH-SY5Y and NGP human neuroblastoma cells were cultured in RPMI 1640, 10% foetal 
bovine serum (FBS). U251 and MO59J human glioblastoma and CHL-1 and WM266-4 
(ATCC #; CRL-9446, CRL-1676) human melanoma cells were cultured in high glucose (4.5 
g/L) DMEM, 10% FBS. All media were from Sigma-Aldrich (Poole, UK). Cells were 
regularly tested for mycoplasma and maintained at 37 °C, 5% CO2 in air (humidified), for up 
to 50 passages. Bortezomib (Janssen Cilag Ltd, High Wycombe, UK) was added to cultures 
in DMSO, and fenretinide (Janssen-Cilag, Switzerland) in ethanol.   
 
CELL DEATH  
Seeding densities (cells per well) for overnight attachment in flat-bottomed 6-well plates 
were 1.5 x 10
5
 for CHL-1, 2.0 x 10
5
 for U251, MO59J, SH-SY5Y and NGP, and 2.5 x 10
5
 for 
WM266-4 cells.  FACScan or FACScalibur flow cytometers (Becton Dickinson 
Immunocytometry systems, Oxford, UK) were used to record the percentage of propidium 
iodide-stained cells with hypodiploid DNA (subG1 peak) as a measure of cell death as 
described previously [Lovat et al., 2008; Lovat et al., 2004].  
 
ANALYSIS OF CELLULAR PROTEINS 
Proteins were analysed by gel electrophoresis and Western blotting, using β-actin as a 
reference after loading in each gel lane equivalent amounts of protein or protein from the 
same number of cells. Protein was measured with a Bradford assay (Pierce Biotech., 
Rockford, IL) using a bovine serum albumin (BSA) standard; cells were counted using a Vi-
Cell counter (Beckman Coulter, Dunstable, UK). Cell lysates were prepared and analysed by 
Western blotting using 4-20% Tris-glycine polyacrylamide gels (Bio-Rad laboratories, Hemel 
Hempstead, UK) as described previously [Armstrong et al., 2007]. Antibodies and dilutions 
used to probe blots were for the GRP78 C-Terminus (Santa Cruz, sc1051; 1:1000 dilution),  
Cleaved Caspase 3 (Cell Signalling, 9661L; 1:500), PERK (Santa Cruz, sc9481; 1:2000), 
IRE1 α (Santa Cruz, sc20790; 1:2000), ATF6 α (Santa Cruz, sc-14253; 1:500), ATF4 
(Calbiochem, PC715; 1:500), , , Ubiquitin (Cell Signalling [P4D1], #3936; 1:1000) and β-
actin (Sigma-Aldrich, A2228; 1:5000). Horseradish peroxidase-conjugated secondary 
antibodies (Upstate Biotechnology, Boston, USA; diluted 1:2000) were used for detection 
with the ECL-plus system (Amersham Biosciences, Little Chalfont, UK) with imaging on a 
Fujifilm FLA-3000 fluorescence imager (Raytek Scientific Ltd, Sheffield, UK). Aida Image 
Analyser version 3.28 was used for densitometric quantification relative to control 
treatments. For ATF4, data were expressed as ‘attomoles/cell’ (amoles/cell) by reference to a 
standard consisting of a 26 kDa His-tagged ATF4 fragment consisting of amino acids 123-
351from Abcam (Cambridge, UK). Estimates of cell and nuclear diameters were obtained 
from phase contrast images and 4',6-diamidino-2-phenylindole (DAPI) -stained confocal 
microscopy images of detached spherical cells. Cytosolic concentrations of ATF4 were then 
estimated using the mean cytosolic volumes calculated from mean cell and nuclear diameters 
of detached cells.   
 
FLOW CYTOMETRY FOR THE INDUCTION OF REACTIVE OXYGEN SPECIES 
(ROS)  
Cells were seeded into 6-well plates (as above) before treatment with ER stress-inducing 
agents over a 6 h time course. After treatment, culture medium was removed and cells 
washed twice in PBS before harvesting by trypsinisation, pelleted by centrifugation at 330 g 
for 5 min and resuspended in 500 µl of 5 µM 5-(and-6)-Carboxy-2',7'-Dichlorofluorescein 
Diacetate (DCFDA, Sigma-Aldrich). Samples were then incubated at 37 °C for 15 min, 
washed twice in ice-cold PBS by centrifugation and stored on ice for analysis by flow 
cytometry. Negative controls were unstained cells and working dye solution alone, and 
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positive controls were cells treated with 25 µM and 50 µM hydrogen peroxide for 6 h 
(Sigma-Aldrich). Flow cytometry data were collected using CellQuest v. 3.3 software using a 
gated amplifier for FL1 (λ 530/30 nm; fluorescein) and a signal threshold for forward and 
side scatter to exclude debris.   
 
SMALL INTERFERING RNA (SIRNA)-MEDIATED KNOCKDOWN OF GRP78  
Knockdown of GRP78 was performed using a double-transfection procedure as described by 
Martin et al (2010) [Martin et al., 2010] using GRP78 siRNA (Hs_HSPA5_6_HP validated 
siRNA; Qiagen, Crawley, UK) or control scrambled siRNA (Qiagen). Knockdown was 
verified by Western blot 24 h after the second transfection or when subsequent cell viability 
and death assays were performed. 
 
REVERSE TRANSCRIPTASE QUANTITATIVE POLYMERASE CHAIN 
REACTION (RT-QPCR)  
Cells were washed (PBS), detached and pelleted by centrifugation, washed once with PBS 
and total RNA extracted using the RNeasy Kit (Qiagen). To prepare cDNA, 0.5 µg RNA was 
combined with 0.5 µg random oligo dT primers, 0.5 mM deoxynucleotide triphosphates 
(dNTPs), and RNase-free water (final volume 20 µl), and incubated at 65 °C for 5 min 
followed by 1 min on ice; 4 µl of first-strand buffer, 1 µl of 0.1 M DTT, 1 µl of RNase 
Inhibitor and 1 µl of Superscript Reverse Transcriptase were added and incubated at 55 °C 
for 60 min before terminating the reaction at 70 °C for 15 min. RNase H (0.5 µl of 5U/µl 
stock) was added, incubated for 20 min at 37 °C and inactivated at 65 °C for 10 min. All 
reagents were from Fermentas (St. Leon-Rot, Germany). Real-time PCR reactions (20 µl 
volume) were carried out in triplicate reactions with PCR primers for GRP78 (GTT CTT 
GCC GTT CAA GGT GG and TGG TAC AGT AAC AAC TGC ATG) and or β-Actin 
control (AAT CTG GCA CCA CAC CTT CTA CA and CGA CGT AGC ACA GCT TCT 
CCT TA) and a 2 x concentration of fast SYBR green master mix containing AmpliTaq fast 
DNA polymerase, SYBR Green-1 dye and dNTPs  with an Applied Biosystems 7500 fast 
real-time PCR machine with SDS software (Applied Biosystems, Carlsbad, California, USA). 
PCR conditions were an initial denaturation at 95 °C (10 min), 50 cycles of 15 s at 95 °C and 
60 s at 60 °C for GRP78 or 15 s at 95 °C, 45 s at 60 °C and 30 s at 72 °C for β-actin followed 
by a final cycle of 30 s at 95 °C and 60 s at 60 °C.  
 
STABLE OVER-EXPRESSION OF GRP78 
Plasmid DNA pcDNA3.0 or pcDNA3.1 (+) containing full-length GRP78 cDNA (a gift from 
Randal Kaufman) were transfected into WM266-4, MO59J and NGP cells in 6-well plates at 
3.0 x 10
5
 cells per well. Plasmid DNA (4 µg in 8 µl) and 12 µl of Lipofectamine 2000 
transfection reagent (Invitrogen, Paisley, UK) were mixed separately with 500 µl OptiMEM 
medium (Invitrogen), combined together at room temperature for 15 min and then diluted 
with 1.5 ml OptiMEM. Culture medium was removed from the cells, the cells washed with 
OptiMEM and then incubated with the transfection mixture for 24 h at 37 °C. Medium was 
then replaced with 3 ml of culture medium containing 10% FBS and 2 mM L-glutamine, and 
incubated for 48 h at 37 °C before selection with geneticin (G418; Invitrogen) at 1500 µg/ml 
for neuroblastoma cells and 2000 µg/ml for melanoma and glioblastoma cells. Transfected 
cells were maintained under G418 selection over 10 passages as a mixed population without 
clonal selection. For experiments, cells were placed in normal culture media for a minimum 
of 3 days prior to the start of each experiment.  
 
CONFOCAL MICROSCOPY  
6 
 
Cells were fixed in 100% ice-cold methanol (Fisher; 30 min), washed in PBS containing 
0.05% Tween 20 (PBS/T; Sigma-Aldrich) and permeabilised in 0.2% Triton X100 (Sigma-
Aldrich, diluted in PBS/T) for 30 min. After blocking with 2% BSA in PBS/T for 1 h, 
samples were washed thrice in PBS/T and incubated with GRP78 primary antibody (Santa 
Cruz; 1:500), in 0.2% BSA-PBS/T for 1 h at room temperature. After washing 3 times in 
PBS/T, blocking in 10% secondary host-antibody-specific serum in PBS/T for 30 min, 
samples were incubated with fluorescently-labelled secondary antibodies diluted in 1% host-
specific serum for 1 h. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich) diluted in PBS/T for 25 min. Stained cells were mounted in Vector Shield 
mounting medium (Vector Laboratories LTD, Peterborough, UK) and imaged within 24 h 
using a x48 objective on a Zeiss LSM 700 inverted confocal scanning microscope (Zeiss, 
Hertfordshire, UK) with averaging of 4 and a frame size of 1024 x 1024 pixels. Each 
experiment included a negative control of unstained cells, as well as secondary antibody only 
to control for non-specific binding. Laser power, optimised on control- stained cells, 
remained the same throughout each experiment. 
 
DATA ANALYSES 
Flow cytometry data were analysed using either WinMDI 2.8 for flow cytometry (Bio-
soft.net) or Cyflogic 1.2.1 (Cyflogic, Turku, Finland). Real time PCR data were analysed 
using SDS2.2 software (Applied Biosystems). The threshold level of expression was set to a 
value on the exponential phase of amplification plots and kept the same for all related primer-
probe experiments. The PCR cycles taken to reach the threshold (Ct) for each sample was 
generated as mean ± 95% confidence intervals (CI) normalised to the β-Actin control data 
and then to the vehicle-treated control samples. Experimental data were expressed as the 
mean of individual experiments ± 95% confidence intervals (95% CI) using Prism 5 
(GraphPad Software Inc; La Jolla, CA, USA) or Sigma Plot 11 (Systat Software Inc; San 
Jose, CA, USA) software. Responses were compared by one- or two-way ANOVA with 
either Dunnett’s or the more-conservative Bonferroni’s post-hoc tests using Prism 5, SPSS 
release 17.0 (IBM; Chicago, IL, USA) or R software. Error bars on all graphs are 95% 
confidence intervals. Dose response parameters were fitted using R and the package drc [Ritz 
and Streibig, 2005].  
 
RESULTS 
RESPONSES TO STRESS-INDUCING AGENTS IN NEUROECTODERMAL CELL 
LINES 
For this work, we studied six cell lines in parallel: two melanoma (CHL1, WM266-4), two 
glioblastoma (U251, MO59J) and two neuroblastoma (SH-SY5Y, NGP) cell lines. 
Fenretinide and bortezomib induce ER stress in melanoma and neuroblastoma cells [Hill et 
al., 2009; Pagnan et al., 2009] by oxidative stress [Lovat et al., 2000] and 26S proteasome 
inhibition, respectively. For the six cell lines, sensitivity and responses to fenretinide and 
bortezomib were characterised in terms of cell death at 24 h and the induction of the stress 
marker ATF4 after 4 h of treatment.  For neuroblastoma and melanoma cells, dose-response 
data indicated maximum cell death of 30-50% but differing sensitivities between cell types 
with 10-fold lower concentrations of bortezomib and 2-fold lower concentrations of 
fenretinide required for neuroblastoma cells (Figure 1A). Conversely, glioblastoma cells had 
higher levels of death (up to 80%; Figure 1A) but within a similar sensitivity range to 
melanoma cells. ATF4 induction was evident in all cell lines but to differing levels and was 
induced to 3- to 10-fold higher levels in melanoma cells compared to neuroblastoma cells 
with intermediate levels of induction observed for glioblastoma cells (Figure 1B).  
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With doses in the mid-range of response, fenretinide rapidly induced reactive oxygen 
species (ROS) in all six cell lines, reaching a plateau after 2-4 h but at higher steady-state 
levels in melanoma than neuroblastoma cells and, again, intermediate values in glioblastoma 
cells (Figure 2A). ATF4 was induced by fenretinide over a similar time course, rather more 
transiently in melanoma cells but remaining elevated in glioblastoma cells (Figure 2B), and to 
lower levels in neuroblastoma cells. In response to bortezomib, ubiquitin decreased and 
ubiquitinated proteins increased steeply during the first 8 h (Figure 2C, E). Greatest increases 
in ubiquitinated proteins, relative to the zero h controls, were produced in glioblastoma cells, 
reaching 20-fold by 24 h, with lower levels in melanoma cells (8- to 10-fold increase by 24 h) 
and very small increases in neuroblastoma cells (1.5-fold increase by 8-24 h; Figure 2C,E). 
ATF4 increased over a similar time scale, reaching a peak by 4-8 h and remaining 
substantially elevated until at least 24 h (Figure 2D).  
 
CELL DEATH AFTER GRP78 KNOCKDOWN  
To test the role of GRP78 in drug and stress sensitivity, GRP78 expression was reduced by 
RNA interference. We have previously reported the siRNA-mediated knockdown of GRP78 
in CHL-1 and WM266-4 cells [Martin et al., 2010] and used the same technique to achieve a 
modest reduction in GRP78 expression of  > 50% in all cell lines, ranging from 56.3% in 
CHL-1 cells [Martin et al., 2010] to 82.3% in U251 glioblastoma cells. Treatment with 
fenretinide or bortezomib resulted in the induction of GRP78 as part of the stress response, 
and this was abrogated after knockdown of GRP78 (Figure 3 and [Martin et al., 2010]).  
Knockdown of GRP78 increases cell death of melanoma cells in response to 
fenretinide or bortezomib [Martin et al., 2010]. For glioblastoma cells, GRP78 knockdown 
also resulted in statistically-significant increases in death in response to fenretinide or 
bortezomib (Figure 3A, B), similar to melanoma cells. Conversely, death was not 
significantly increased in either of the neuroblastoma cell lines (Figure 3C, D) and there was 
a small but statistically-significant decrease in death of fenretinide-treated SH-SY5Y cells 
(Figure 3D). These results were confirmed in experiments to measure the effect of GRP78 
knock-down on stress-induced inhibition of cell viability (Figure S1). 
 Increased sensitivity to stress would be predicted from GRP78 knockdown, but in 
view of the fact that GRP78 interacts directly with the stress sensors, it is important to ask if 
there are correlated or compensatory alterations in expression of PERK, IRE1 and ATF6 as a 
result of GRP78 knockdown. For melanoma cells, there was no apparent effect on GRP78 
knockdown on ATF6 or PERK expression but a 1.3-fold increase in IRE1 expression (Figure 
4A). UPR activator expression overall was reduced slightly (by up to 0.9-fold) in 
glioblastoma cells (Figure 4B). Conversely, there were no significant changes in UPR 
activator levels in the neuroblastoma cells in response to GRP78 knockdown (Figure 4C). 
Overall, the magnitudes of changes in UPR activator levels were small in comparison to the > 
50% knockdown of GRP78. 
 
RESISTANCE AND SENSITIVITY TO STRESS AFTER OVER-EXPRESSION OF 
GRP78  
To test the prediction that increasing GRP78 expression would increase resistance to stress, 
GRP78 was stably over-expressed in one cell line of each type: WM266-4 melanoma, MO59J 
glioblastoma and NGP neuroblastoma cells. Compared to cells stably transfected with empty 
vector, in GRP78-transfected cells, GRP78 mRNA was increased 1.5- to 2-fold. Similarly, 
GRP78 protein increased by 1.7-fold in melanoma, 1.96-fold in glioblastoma and 1.5-fold in 
the neuroblastoma cells (Figure 5A, B) and this was confirmed by confocal microscopy 
which also showed increased GRP78 staining with similar intracellular distributions to 
control cells (Figure 5C, D).   
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Unlike WM266-4 and MO59J cells, over-expression of GRP78 in NGP 
neuroblastoma cells resulted in morphological changes: cells increased in size with a decrease 
in dendrites and an increase in detachment (Figure 6A, B). Over-expression of GRP78 in all 
three cell lines affected sensitivity to fenretinide or bortezomib with reduced death in 
WM266-4 and MO59J cells (Figure 6C, D). However, NGP neuroblastoma cells showed 
increased sensitivity to stress and the death of the vehicle-treated control cells was increased 
compared to vector-transfected or wild-type cells (Figure 6E). These effects, although 
relatively small, were mirrored by increased viability of WM266-4 and MO59J cells over-
expressing GRP78 and treated with fenretinide or bortezomib, but decreased viability of NGP 
cells under the same conditions (Figure S2). For confirmation of effects on neuroblastoma 
cells, we transiently over-expressed GRP78 in NGP cells in the absence of ER stress. Death 
of these cells was increased in a GRP78-dose-dependent manner 24 h after transfection 
(Figure 6F) and confirmed the results from stable over-expression experiments that, contrary 
to prediction, higher levels of GRP78 expression increased neuroblastoma cell death and 
reduced survival. 
With respect to biochemical markers of cell stress and death, the induction of ATF4 
and cleavage of caspase-3 in response to fenretinide or bortezomib were measured (Figure 
7A-C). In stressed WM266-4 and MO59J cells overexpressing GRP78, ATF4 induction and 
caspase-3 cleavage were significantly reduced. Conversely, the over-expression of GRP78 
increased ATF4 induction in NGP neuroblastoma cells treated with bortezomib but decreased 
ATF4 induction in response to fentretinide compared to control vector-transfected cells; 
unexpectedly, however, caspase-3 cleavage in these NGP cells was also reduced in response 
to both drugs, despite the increased levels of cell death (Figure 6) produced under these 
conditions.  
For all three cell types there were no significant differences in UPR activator 
expression between wild-type cells and those stably transfected with empty vector; in 
contrast, IRE1 expression was increased 2-fold in WM266-4 cells over-expressing GRP78 
and accompanied by a small decrease in ATF6 expression (Figure 7D,E).  In MO59J cells 
over-expressing GRP78, PERK expression was reduced by 50% whereas for NGP cells, 
GRP78 over-expression resulted in increased levels of all three UPR activators, with marked 
≈3-fold increases in IRE1 and ATF6, as well as a small increase in PERK.  
 
STRESS AFTER GRP78 OVER-EXPRESSION  
These results provide evidence that neural-crest-derived tumour cell types differ in how 
stress-sensor functions of GRP78 are modulated to determine the outcome of stress. Given 
the dynamic nature of cellular homeostatic control, it is important to ask if stress apparently 
experienced by cells is altered by GRP78 over-expression. In WM266-4 and MO59J cells 
stably over-expressing GRP78, fenretinide-induced ROS was inhibited; however, this was not 
the case when GRP78 was over-expressed in NGP neuroblastoma cells (Figure 8A). With 
respect to cells treated with bortezomib, the accumulation of ubiquitin-tagged proteins was 
reduced by GRP78 over-expression in WM266-4 and MO59J cells (Figure 8B) but increased 
in NGP cells. Thus, reduced death in response to bortezomib in cells over-expressing GRP78 
was associated with a reduced ability of bortezomib to inhibit 26S proteasome activity. 
Conversely, although fenretinide-induced ROS and death were reduced in melanoma and 
glioblastoma cells by over-expressing GRP78, in neuroblastoma cells the higher levels of 
fenretinide-induced death with GRP78 over-expression were not accompanied by increased 
ROS (Figure 8A). 
 
DISCUSSION 
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Fenretinide and bortezomib both activate the PERK/ATF4 arm of the UPR [Lai and Wong, 
2008; Obeng et al., 2006] but do so to differing extents. The steady accumulation of 
ubiquinated proteins induced with bortezomib implies a sustained effect with stress 
increasing over time, reflected by the high and continued expression of the ER stress-
inducible marker ATF4. In contrast, ROS induced by fenretinide reached a maximum after 
only a few hours and induced a transient ATF4 expression, implying adaptation to higher 
ROS levels. Despite apparent differences in mechanisms, levels of death induced by each 
agent were apparently cell-type specific. Although we discuss our data in the context of 
intracellular GRP78, some studies have suggested that using antibodies to modulate activity 
of cell-surface GRP78 may affect stress sensitivity [Liu et al., 2013; Misra et al., 2009]. 
However, we have been unable to demonstrate (Martin, Lovat, Redfern unpublished data) a 
convincing effect of an anti-GRP78 antibody on increasing the sensitivity of melanoma, 
glioblastoma or neuroblastoma cells to stress-inducing drugs. Therefore, it is likely that the 
role of GRP78 in the context of our studies is mediated by intracellular signalling pathways.  
 Reducing GRP78 expression may increase stress sensitivity, perhaps by reduced 
chaperone capacity or by priming the UPR as a consequence of excess unbound UPR 
activators. As with the melanoma and glioblastoma cell lines used for this study, increased 
stress sensitivity resulting from reductions in GRP78 expression has also been reported for 
breast cancer and HeLa cells [Cook et al., 2012; Suzuki et al., 2007]. The consequence of 
GRP78 knockdown is likely, on the basis of simple mass-action models of the association 
and dissociation kinetics of GRP78 with each of the UPR activators, to lead to increases in 
levels of free IRE1, PERK and ATF6. Although IRE1 can have pro-survival and pro-
apoptotic functions, such potential changes in UPR activators could drive increased 
sensitivity of cells to stress. However, neuroblastoma cells did not show increased sensitivity 
to stress after GRP78 knockdown, implying a contextual relationship between GRP78, UPR 
activators and stress sensitivity. 
The converse experiment, increasing GRP78 levels by stable over-expression, 
produced the predicted result in WM266-4 melanoma and MO59J glioblastoma cells, 
reducing death in response to stress. In contrast to transient knockdown experiments, stable 
over-expression of GRP78 was accompanied by variable but relatively large changes in UPR 
activator expression, with reductions in PERK in the glioblastoma cells and increased IRE1 
but decreased ATF6 in melanoma cells. The contribution of these changes in UPR activator 
expression to decreased stress sensitivity is uncertain because GRP78 over-expression in 
these cells was also accompanied by reduced stress in response to fenretinide or bortezomib. 
In marked contrast, GRP78 over-expression in the NGP neuroblastoma cells increased stress-
induced death, possibly as a result of the large and unexpected increases in expression of all 
three UPR activators. There was also a marked phenotypic change in these cells which may 
indicate a functional role for GRP78 in morphogenesis and differentiation, either directly 
[Barnes and Smoak, 2000] or as a result of changes in expression of UPR activators, 
particularly IRE1 or downstream transcription factors such as XBP1 [Cho et al., 2013], or 
interaction with other chaperones [Gunter and Degnan, 2007].  
GRP78 is involved in the regulation of redox levels as a stress response via the 
PERK-dependent activation of Nrf2 and up-regulation of redox-defensive genes [Cullinan et 
al., 2003; Niture et al., 2010]. Others have shown that GRP78 knockdown can increase 
endogenous ROS levels, but subsequent effects of stress-inducing agents are unpredictable 
[Chang et al., 2012]. Therefore, reduction in ROS in melanoma and glioblastoma cells over-
expressing GRP78 and treated with fenretinide is consistent with a role of GRP78 in redox 
regulation, although whether mediated directly by GRP78 or indirectly via PERK is 
unknown. Reductions in bortezomib-induced accumulation of ubiquitinated proteins in 
melanoma and glioblastoma cells over-expressing GRP78 may result from an increase in 
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chaperone capacity. GRP78 may have a role in ERAD by interacting with the E3 Ubiquitin 
ligase HRD-1 [Sasagawa et al., 2007] and a ubiquitin hydrolase [Fang et al., 2012]; such 
interactions in cells over-expressing GRP78 could decrease the accumulation of ubiquitinated 
proteins in response to bortezomib. GRP78 can also inhibit caspases mediating ER-stress-
induced apoptosis [Reddy et al., 2003], an additional mechanism that could lead to decreased 
stress sensitivity of WM266-4 and MO59J cells over-expressing GRP78, and to increased 
sensitivity under knockdown conditions. Thus, in melanoma and glioblastoma cells under 
conditions of high GRP78 expression, reduced stress sensitivity may result from reductions in 
free UPR activators (predicted by considering mass-action relationships), caspase inhibition 
and reduced levels of stress (greater first-line stress defences); conversely, after GRP78 
knockdown, higher levels of free UPR activators and low caspase inhibition, potentially 
coupled with reduced stress defences, would increase stress sensitivity. 
GRP78 seems to act as a buffer for regulating IRE1 activity [Pincus et al., 2010] and 
for neuroblastoma cells it is possible that the effect of manipulating GRP78 levels may be 
driven by IRE1 and interactions coupling IRE1 to death pathways other than the PERK/ATF4 
axis. Levels of ubiquitinated-protein accumulation in these cells were, compared to 
melanoma and glioblastoma cells, high under basal conditions and changed little in response 
to bortezomib. As well as binding to GRP78, IRE1 interacts with HRD-1 [Gao et al., 2008], 
presenilin-1 [Niwa et al., 1999], TRAF2 [Urano et al., 2000], TAO kinase 3 [Yoneda et al., 
2001] and MAP3K5 (ASK1) [Nishitoh et al., 2002]. TRAF2, TAO Kinase 3 and ASK1 are 
components of the ASK1-JNK pathway leading to apoptosis by both caspase-dependent and -
independent mechanisms; in neuronal cells, caspase-independent apoptosis via a kinase-
independent  ASK1/Daxx interaction [Charette et al., 2001] and JNK-dependent pathways 
[Kamalden et al., 2012] have been described. As caspase-3 cleavage was not a feature of 
increased stress-induced cell death in NGP cells over-expressing GRP78, apoptosis under 
these conditions may be driven by caspase-3-independent processes resulting from increased 
IRE1 levels. IRE1 is also a component of the ERAD/ubiquitination system via its interaction 
with HRD-1 [Gao et al., 2008] and in the transcriptional regulation of ERAD components 
[Lee et al., 2003]; therefore, increased accumulation of ubiquitinated proteins in bortezomib-
treated cells may also result from higher IRE1 levels. 
It is clear from this and other studies that GRP78 has complex roles in cell signalling, 
stemming from its interactions from the three stress sensors as well as with other proteins. In 
breast cancer cells, apoptosis may be regulated by interactions between GRP78 and the pro-
apoptotic BH3-domain protein Bik [Zhou et al., 2011]; thus, changes in the availability of 
free Bik as a result of GRP78 over-expression or knockdown could be a contributory factor to 
the increased resistance or sensitivity, respectively, seen in melanoma and glioblastoma cells. 
Nevertheless, the results from this study suggest that cell-type specific differences in the 
relationships between GRP78 and the UPR activators, particularly IRE1, may determine 
differential sensitivity to ER stress. For IRE1 there are likely to be complex relationships 
between monomer (kinase inactive) IRE1, active IRE1 oligomers, GRP78 and IRE1-
interacting proteins such as TRAF2, HRD-1, ASK1 and TAO Kinase 3 and interpreting the 
outcome of changes in expression of one or more of these components will require 
computational approaches to couple signalling fluxes to cellular outcome in terms of 
adaptation (homeostasis/repair) or cell death, coupled with experimental measurements of 
stoichiometric relationships between GRP78 and UPR activators in relation to stress 
sensitivity. 
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Figure 1:  
Response of neuroectodermal cells to fenretinide or bortezomib. A, dose-response curves for 
cell death after 24 h drug treatment (% apoptosis or the % cells in the subG1 fraction in flow 
cytometry of propidium iodide-stained cells). Open symbols and dotted lines are responses to 
fenretinide (dose, top axis) and filled symbols and solid lines are responses to bortezomib 
(dose, bottom axis). Curves are 4-parameter sigmoidal dose response curves fitted with 
package ‘drc’ in R. B, dose-dependent induction of ATF4 after 4 h treatment with fenretinide 
or bortezomib, expressed as amoles/cell estimated from Western blots with purified ATF4 
protein fragment as standard, in response to fenretinide- (top axis) or bortezomib (bottom 
axis). Symbols and lines as in A. 
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Figure 2: 
Induction of stress in response to fenretinide or bortezomib. Time course of induction of ROS 
(vertical panel A) and ATF4 (vertical panel B) in melanoma (top graph), glioblastoma (centre 
graph) and neuroblastoma (bottom graph) cells treated with fenretinide (10 M or 5 M for 
melanoma/glioblastoma and neuroblastoma cells, respectively). Time courses of induction of 
ubiquitinated proteins (vertical panel C) and ATF4 (vertical panel D) after treatment of cell 
lines with bortezomib (200 nM or 20 nM for melanoma/glioblastoma and neuroblastoma 
cells, respectively. Examples of Western blots used for densitometric quantification of 
protein ubiquitination are shown in horizontal panel E. Error bars are 95% confidence 
intervals. 
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Figure 3: 
SiRNA-mediated knockdown of GRP78 measured by Western blotting and densitometric 
quantification (left column) and sensitivity to ER-stress-induced cell death (right column). 
Published data for melanoma cells from the study of [Martin et al., 2010] are shown in panels 
A (CHL-1 cells) and B (WM266-4 cells) to facilitate comparison with MO59J (Panel c) and 
U251 (Panel D) glioblastoma cells, and NGP (Panel E) and SH-SY5Y (Panel F) 
neuroblastoma cells. . Cells were transfected with either scrambled control siRNA (left-hand 
group of three bars on each graph) or GRP78 siRNA (right-hand group of three bars on each 
graph) before treatment with control vehicle (white or open bars), fenretinide (grey bars; 10 
M or 5 M for glioblastoma and neuroblastoma cells, respectively) or bortezomib (black 
bars; 200 nM or 20 nM for glioblastoma and neuroblastoma cells, respectively) for 24 h and 
then harvested for Western blotting and 
measurement of cell death. In the left-hand 
column, bar height is mean expression of 
GRP78 relative to the control-transfected 
and control-vehicle-treated cells and 
corrected for loading using the β-actin 
intensity; example blots are shown above 
each graph. For all cell lines, GRP78 
expression (left-hand column) was 
reduced relative to a scrambled control 
siRNA by > 50% (one-way ANOVA, 
Dunnett’s post hoc test, P < 0.0001). In the 
right-hand column, bar height is mean 
relative cell death (fold change; measured 
by flow cytometry) expressed relative to 
untreated, scrambled control-transfected 
cells. In glioblastoma cells, GRP78 
knockdown increased death in response to 
fenretinide or bortozomib (across siRNA 
treatments, one-way ANOVA, Dunnett’s 
post hoc test: MO59J P < 0.0001; U251 P 
< 0.001). There was no increased death in 
response to fenretinide or bortezomib after 
GRP78 knockdown in the neuroblastoma 
cells (P>0.05) but in SH-SY5Y cells 
treated with fenretinide there was a small 
decrease in death (one-way ANOVA; 
Dunnett’s, P < 0.05). On the graphs: ***, 
P <0.001; **, P < 0.01; *, P<0.05; the 
direction (increase or decrease) of 
significant change is indicated by an 
arrow. 
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Figure 4: 
Expression of the UPR activators, PERK, IRE1 and ATF6 in melanoma (A), glioblastoma 
(B) and neuroblastoma cells (C) after siRNA mediated knockdown of GRP78, relative to 
control (scrambled) siRNA-transfected cells and corrected for β-actin intensity. Example 
blots are shown to the right of each graph. On each graph, white/open bars are data for 
control transfected cells (c) and black bars are GRP78 siRNA-transfected cells (G). Data 
were analysed by two-way ANOVA for each cell type: initially to test the effect of treatment 
by cell line (main effects and interactions) for each UPR activator, and then to test the overall 
relative response with respect to relative UPR activator expression and treatment (main 
effects and interactions). The ordinate scale is from 0.5 to 1.5. For the melanoma cell lines, 
there was no significant effect of GRP78 knockdown on ATF6 or PERK expression (two-
way ANOVA; P>0.1 and P>0.8, respectively) but a 1.3-fold increase in IRE1 expression 
(P=0.007; cell line and cell:treatment interactions P>0.9). UPR activator expression overall 
was reduced (up to 0.9-fold) in glioblastoma cells (treatment effect P=0.009; differences 
between UPR activator type and interactions, P>0.8). **, P < 0.01; *, P<0.05. 
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Figure 5: 
Over-expression of GRP78 cDNA in a melanoma (WM266-4), glioblastoma (MO59J) and 
neuroblastoma cell line (NGP) stably transfected with the empty pcDNA3.0 vector or 
pcDNA3.1 (+) containing GRP78 cDNA (G). A, expression of GRP78 mRNA measured by 
quantitative real-time PCR in wild-type cells (c; open bars), vector-transfected cells (v; grey 
bars) and GRP78-transfected cells (G; black bars). B, expression of GRP78 protein, measured 
by densitometry of Western blots (details as for A) was significantly increased in all three 
cell lines (one-way ANOVA, F2, 54 = 65.054, P < 0.0001). C, GRP78 expression (confocal 
images, red signal) in wild-type WM266-4, 
MO59J and NGP cells (white scale bar = 20 
µm), and cells stably transfected with empty 
vector or vector containing GRP78 cDNA. 
The fixed and stained cells were also 
stained with DAPI (blue staining) to reveal 
the nuclei. The staining intensity for GRP78 
was significantly increased (one-way 
ANOVA F8, 89 = 45.4, P < 0.0001). D, 
Quantification of fluorescent intensities 
from confocal images (30 cells per 
condition) for wild-type, vector-transfected 
and GRP78-transfected WM266-4, MO59J 
and NGP cells (legend details as in A): 
there was significantly-increased staining in 
cells stably over-expressing GRP78 (P < 
0.01) and no significant difference between 
the wild-type cell lines and control vector-
transfected cells (P > 0.05). In all graphs, 
data are expressed relative to wild-type cells 
and the error bars are 95% CI. Images are 
representative of three experiments, 3 
images per experiment. ***, P <0.001; **, P 
< 0.01; *, P<0.05. 
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Figure 6: 
Morphology and cell death in cells over-expressing GRP78. A, phase-contrast micrographs of 
WM266-4 melanoma (top row), MO59J glioblastoma (middle row) and NGP neuroblastoma 
cells (bottom row) representing wild-type cells (left column), vector control cells (centre 
column) and cells stably transfected with GRP78 cDNA (right column). B, cell area in 
control (c; open bar), vector-transfected (v; grey bar) and GRP78-transfected (GRP78; black 
bar) NGP cells (one-way ANOVA, F2, 29 = 
62.4, P < 0.0001). C, D and E, mean 
percentage cell death (bar heights) as 
measured by flow cytometry in wild-type 
(wt; left-hand group), vector transfected 
(vector; centre group) and GRP78-
transfected (GRP78; right-hand group) 
WM266-4 (graph C), MO59J (graph D) 
and NGP (graph E) cells treated with 
control vehicle (C, open bars), fenretinide 
(F; grey bars; 10 M or 5 M for 
melanoma/glioblastoma and 
neuroblastoma cells, respectively) or 
bortezomib (B; black bars; 200 nM or 20 
nM for melanoma/glioblastoma and 
neuroblastoma cells, respectively) for 24 
h. GRP78 over-expression in WM266-4 
and MO59J cells decreased fenretinide- or 
bortezomib-induced cell death (one-way 
ANOVA, P < 0.0001) but in NGP 
neuroblastoma cells increased sensitivity 
to stress (one-way ANOVA, P < 0.01 or P 
< 0.0001 for fenretinide or bortezomib, 
respectively). F, % cell death (measured 
by flow cytometry) in wild-type NGP cells 
24 h after transient transfection with 
increasing amounts of GRP78 cDNA 
(total plasmid DNA transfected kept 
constant with compensating amounts of 
empty vector); symbols represent separate 
experiments. Curve is cubic function of 
best fit. In the absence of ER stress, 
GRP78 cDNA increased cell death dose-
dependently (one-way ANOVA, F5, 17 = 
138.1, P < 0.0001). Error bars are 95% CI. 
***, P <0.001; **, P < 0.01; *, P<0.05; the 
direction (increase or decrease) of 
significant change is indicated by an 
arrow. 
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Figure 7: 
The consequences of GRP78 over-expression: downstream markers of ER stress and cell 
death after treatment with ER-stress inducing drugs, and UPR activator expression in cells 
over-expressing GRP78 compared to wild-type cells or cells transfected with empty vector. 
An analysis of caspase-3 cleavage and ATF4 expression in WM266-4 (left column), MO59J 
(centre column) and NGP cells (right column) is shown using Western blotting in A, with 
densitometric quantification in B (caspase-3 cleavage) and C (ATF4 expression). Bar heights 
and the mean with 95% CI from 3 experiments expressed relative to control-vehicle-treated 
cells. Caspase-3 cleavage and ATF4 induction in response to fenretinide (F) or bortezomib 
(B) was reduced in WM266-4 and MO59J cells overexpressing GRP78 (one-way ANOVA 
for ATF4 and caspase 3 cleavage, fenretinide P < 0.001 or bortezomib P < 0.001). In NGP 
neuroblastoma cells over-expressing GRP78, caspase-3 cleavage was reduced compared to 
control vector-transfected cells (P<0.001) in response to fenretinide or bortezomib; 
conversely ATF4 induction in response to bortezomib was increased (P < 0.0001) but 
reduced in response to fenretinide treatment (P<0.01).. D, Western blots for UPR activator 
expression (PERK, IRE1 and ATF6) for the wild-type (c), vector-transfected (v) and GRP78-
transfected (G) WM266-4, MO59J and NGP cells. E, Densitometric quantification, relative to 
wild-type cells: in WM266-4 cells over-expressing GRP78 there was a 2-fold increase in 
expression of IRE1 and a 
small decrease in ATF6 
expression (one-Way 
ANOVA with Dunnett’s, 
comparing stably-
transfected cells to wild-
type, P < 0.0001 for 
IRE1 and P < 0.01 for 
ATF6) while MO59J 
cells over-expressing 
GRP78 had a 50% 
reduction in PERK (P < 
0.001). In NGP cells, 
over-expression of 
GRP78 increased levels 
of all three UPR 
activators with marked 
≈3-fold increases in 
IRE1 and ATF6 (P < 
0.0001) and a small 
increase in PERK 
(P<0.05). ***, P <0.001; 
**, P < 0.01; *, P<0.05; 
the direction (increase or 
decrease) of significant 
change is indicated by an 
arrow. 
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Figure 8: 
Change in drug-induced stress intensity as a result of GRP78 over-expression. A, the 
induction of ROS 6 h after treatment of wild-type (c; open bars), vector-transfected (v; grey 
bars) or GRP78-over-expressing (G; black bars) cells with fenretinide (10 M or 5 M for 
melanoma/glioblastoma and neuroblastoma cells, respectively). Over-expression of GRP78 
inhibited fenretinide-induced ROS in WM266-4 and MO59J cells (one-way ANOVA, P < 
0.0001) but not in NGP neuroblastoma cells (one-way ANOVA, P > 0.05). B, the induction 
of ubiquitinated proteins 8 and 24 h after treatment of wild-type (c; open bars), vector-
transfected (v; grey bars) or GRP78-over-expressing (G; black bars) cells with bortezomib 
(200 nM or 20 nM for melanoma/glioblastoma and neuroblastoma cells, respectively; bar 
heights are relative to wild-type cells). Accumulation of ubiquitin-tagged proteins was 
reduced by over-expression of GRP78 in WM266-4 and MO59J cells (one-way ANOVA, 
P<0.05) but increased in NGP neuroblastoma cells (P < 0.001). Error bars are 95% CI. ***, P 
<0.001; **, P < 0.01; *, P<0.05; the direction (increase or decrease) of significant change is 
indicated by an arrow. 
 
FigureS1: the effect of GRP78 knockdown on cell viability. 
 
 
 
 
The effect of reduced GRP78 expression on sensitivity of glioblastoma and neuroblastoma cells to 
fenretinide and bortezomib: inhibition of cell viability. Data for CHL-1 and WM266-4 melanoma cells 
were published in (Martin et al., 2010).  A & B, MO59J and U251 glioblastoma cells, respectively; C & 
D, NGP and SH-SY5Y neuroblastoma cells, respectively. Cells were transfected with 40 nM GRP78 
specific SiRNA (GRP78 SiRNA) in comparison to a scrambled control (Con SiRNA) prior to treating the 
samples with control vehicle (Con), fenretinide (FenR; grey bars; 10 µM for glioblastoma cells or 5 
µM for neuroblastoma cells) or bortezomib (Bort; black bars: 200 nM for glioblastoma cells or 20 nM 
for neuroblastoma cells) for 24 h. Cell viability was measured using the MTS colorimetric assay. Data 
are expressed as the mean of 3 replicate experiments relative to control-vehicle-treated cells  ± 95 % 
CI. Data for melanoma cells (Martin et al., 2010) have been analysed together with the glioblastoma 
and neuroblastoma data:   In melanoma and glioblastoma cells, GRP78 knock-down resulted in a 
significant increase in either fenretinide or bortezomib-induced inhibition of cell viability (One-way 
ANOVA with Dunnett’s post hoc correction for CHL-1 melanoma cells and either glioblastoma cell 
line treated with fenretinide P < 0.001 or WM266-4 with fenretinide and bortezomib or CHL-1, 
MO59J and U251 treated with bortezomib P < 0.0001, respectively). Although there was an apparent 
reduction in cell viability in untreated cells in response to a decrease in GRP78 expression, this was 
not significant (P > 0.05). CHL-1 and WM266-4 metastatic melanoma cells also demonstrated 
significant differences in response (F1, 47 = 10.3, P < 0.01), with WM266-4 cells being less affected by 
GRP78 knock-down. Data for the effect of GRP78 knock-down on ER stress-induced inhibition of 
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neuroblastoma cell viability also demonstrated no significant differences between cells transfected 
with control or GRP78 specific siRNA (P > 0.05). 
For cell viability measurments, 5000 cells per well were cultured in flat-bottomed 96-well 
tissue culture plates (Helena Biosciences; Gateshead, UK) in 100 µl of tissue culture medium and 
allowed to attach overnight before treatment.  Cell viability was measured subsequently from 
absorbance at 490 nm in a FLUOstar Omega (BMG labtech, Aylesbury, UK) plate reader using the 
CellTiter 96 Aqueous One Solution reagent (Promega, Southampton, UK; MTS assay) according to the 
manufacturer’s instructions. 
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Figure S2: the effect of stable GRP78 over-expression on cell viability. 
 
 
 
 
The effect of GRP78 over-expression on sensitivity to ER stress-induced inhibition of cell viability. WM266-4 
melanoma (A), MO59J glioblastoma (B) and NGP neuroblastoma (C) cells: wild-type (control),  stably 
transfected with empty vector (pcDNA3.0) or GRP78 cDNA in pcDNA3.1 were treated with control vehicle 
(C),  fenretinide (F, 10 µM for melanoma and glioblastoma or 5 µM for neuroblastoma) or bortezomib (B, 
200 nM for melanoma and glioblastoma or 20 nM for neuroblastoma) for 24 h and cell viability assessed 
using the MTS assay. Data were expressed as the mean values of 3 experiments of 8 individual replicates ± 
95% confidence intervals. There was a significant reduction of fenretinide and bortezomib induced inhibition 
of cell viability in melanoma and glioblastoma cell, in comparison to controls (A & B; One-way ANOVA with 
Bonferroni post hoc corrections, P < 0.0001 for either agent, in both cancer types). Conversely, 
neuroblastoma cells overexpressing GRP78 showed an increase in sensitivity to ER stress (C; One-way 
ANOVA with Bonferroni post hoc corrections P < 0.001 for fenretinide and P < 0.0001 for bortezomib). 
